In our cohort of patients with ER/PgR-positive and HER2-negative BC undergoing adjuvant hormonal treatment with AI, we demonstrated poor differences, in all the bacterial consortia, between patients who documented disease relapse during AI (cases) and patients who did not experienced relapse (controls). Here, ESR1 is linked to breast cancer.